Global Desmoid Tumors Market Research Report- Forecast till 2023

Global Desmoid Tumors Market Research Report- Forecast till 2023

ID: MRFR/HC/3431-HCRR | | Region: Global | 85 pages | Half-Cooked Research Reports

Desmoid Tumors Market Research Report Information: Diagnosis (Biopsy, Electron Microscopy, Immunohistochemical Analysis), Treatment (Surgery, Radiation, Chemotherapy, Medication, Hormone, Molecular Targeted Therapy), End User - Global Forecast till 2023 


Market Scenario


Desmoid tumors are also known as desmoid fibromatosis. These benign growths occur very rarely in the general population. Desmoid tumor usually develops in the fibrous tissue of the body, commonly in the arms, legs or midsection, and sometimes in the head and neck. The term desmoid was derived from the Greek word desmos, which means tendonlike. Desmoid tumors appear as well-differentiated, and firm overgrowths of fibrous tissue. According to the U.S National Library of Medicine, Desmoid tumors are very rare as the rate of occurrence is estimated to be 1 to 2 per 500,000 people worldwide. It is also stated that nearly 900 to 1,500 new cases are registered per year in the United States. Tumors associated with familial adenomatous polyposis (FAP) are less common than sporadic desmoid tumors.


On molecular level, desmoid tumor is characterized by one of the two mutations in the gene i.e. mutations in the adenomatous polyposis coli (APC) gene, or in the β-catenin gene, CTNNB1. During diagnostic procedures CTNNB1 mutation is detected, especially, when pathological differential diagnosis is difficult.


According to the Desmoid Rare Foundation, individuals within the age group of 15 and 60 are more likely to get affected by this condition. It is also stated that the condition is more prevalent in women than in men (2:1).


For the diagnosis of desmoid tumor there are many non-invasive methods available to detect desmoid tumor which include ultrasound, MRI scan, and CT scan. The actual diagnosis of this tumor can be made only after examining a small piece of the tumor by a trained pathologist.


The symptoms of desmoid tumors include a painless swelling or lump, pain and obstruction of the bowels, limping, pain caused by compressed nerves or muscles, and others.


The most commonly used treatment options for desmoid tumors are anti-inflammatory medication, Chemotherapy, Hormone therapy, and surgery among others. Various new therapies are under investigation such as Angiogenesis inhibitors, and Chemotherapy agents. As mutations in the CTNNB1 gene is found to be most commonly occurring in desmoid tumor. So, it is expected that very soon mutation analysis be used to predict the risk of recurrence and to aid in designing individual therapies.


Notably, the market is expected to expand in the near future due to rising demand of effective chemotherapeutic agents, high unmet needs of current treatment, and increase in research and development expenditure.


Despite these drivers, there are some issues associated with desmoid tumors market. High cost of treatment & management of desmoid tumors and related disorders, and lack of infrastructure in the middle and low income countries may hamper the growth of the market.


It is estimated that desmoid tumors market is expected to grow at a CAGR 4.5% during the forecast period of 2017-2023.


Intended Audience



  • Hospitals

  • Surgical equipment Companies

  • Diagnostic clinics

  • Research and Development (R&D) Companies

  • Government Research Institute

  • Academic Institutes and Universities 


Figure: Global Desmoid Tumors Market, By Region Market Share, 2017 (%)

Desmoid Tumors Market


Sources: Annual reports, Press release, White paper, Company presentation 


Segmentation


The desmoid tumors market is segmented on the basis of diagnosis, treatment, and end-user.


On the basis of diagnosis, market is segmented into biopsy, electron microscopic examination, immunohistochemical analysis, others


On the basis of treatment, market is classified into surgery, radiation therapy, anti-inflammatory medication, hormone therapy, chemotherapy, novel molecular-targeted therapy, others. Novel molecular-targeted therapy is further segmented into gleevec based therapy, and sorafenib based therapy


On the basis of end-user, market is segmented into hospital, clinics, and others. 


Regional Analysis


The Americas dominate the desmoid tumors market owing to the rising awareness among people, and increasing healthcare expenditure. As per the facts suggested by the Centers for Disease Control and Prevention (CDC), it is found that out of total annual healthcare expenditure, 86% is for people with chronic health conditions in the United States. Furthermore, increasing participation of bigger players and new marketers towards advancement in treatment approaches have also attracted a great deal of attention.


Europe holds the second position in the desmoid tumors market. It is expected that the support provided by government bodies for research & development and improvement in reimbursement policies in healthcare will drive the market in Europe region.


Asia Pacific is the fastest growing desmoid tumors market owing to the huge patient pool and developing healthcare technology.


The Middle East & Africa has the lowest market for desmoid tumors market due to lack of technical knowledge and poor medical facilities. 


Key Players


Some of key the players in the market are Amgen Inc., Novartis AG, Abbott Laboratories, Bayer AG, AbbVie Inc., Beckman Coulter Inc., Stryker Corporation, Debiopharm Group, F. Hoffmann-La Roche Ltd, and others. 


Research Methodology


Global Desmoid Tumors Market


Sources: Annual reports, Press release, White paper, and Company presentation

Table of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Desmoid Tumor Market, by Diagnosis

6.1 Introduction

6.2 Biopsy

6.2.1 Market Estimates & Forecast, 2016 – 2023

6.3 Electron Microscopic Examination

6.3.1 Market Estimates & Forecast, 2016 – 2023

6.4 Immunohistochemical Analysis

6.4.1 Market Estimates & Forecast, 2016 – 2023



Chapter 7. Global Desmoid Tumor Market, by treatment

7.1 Introduction

7.2 Surgery

7.2.1 Market Estimates & Forecast, 2017 – 2023

7.3 Radiation Therapy

7.3.1 Market Estimates & Forecast, 2017 – 2023

7.4 Anti-Inflammatory Medication

7.4.1 Market Estimates & Forecast, 2017 – 2023

7.5 Hormone Therapy

7.5.1 Market Estimates & Forecast, 2017 – 2023

7.6 Chemotherapy

7.6.1 Market Estimates & Forecast, 2017 – 2023

7.7 Novel Molecular-Targeted Therapy

7.7.1 Market Estimates & Forecast, 2017 – 2023



Chapter 8. Global Desmoid Tumor Market, by End User

8.1 Introduction

8.2 Hospitals

8.2.1 Market Estimates & Forecast, 2017 – 2023

8.3 Clinics

8.3.1 Market Estimates & Forecast, 2017 – 2023

8.4 Others

Chapter 9. Global Desmoid Tumor Market, by Region

9.1 Introduction

9.2 Americas

9.2.1 North America

9.2.1.1 US

9.2.1.1 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 UK

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe



9.4 Asia Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 Republic of Korea

9.4.6 Rest of Asia Pacific

9.5 The Middle East & Africa

9.5.1 United Arab Emirates

9.5.2 Saudi Arabia

9.5.3 Oman

9.5.4 Kuwait

9.5.5 Qatar

9.5.6 Rest of the Middle East & Africa

Chapter 10 Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

10.3.1 Key Developments

Chapter 11 Company Profiles

11.1 Amgen Inc.

11.1.1 Company Overview

11.1.2 Types Overview

11.1.3 Financials

11.1.4 SWOT Analysis

11.2 Novartis AG

11.2.1 Company Overview

11.2.2 Types Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 Abbott Laboratories

11.3.1 Company Overview

11.3.2 Types Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 Bayer AG

11.4.1 Company Overview

11.4.2 Types/Business Segment Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 AbbVie Inc.

11.5.1 Company Overview

11.5.2 Types Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.6 Beckman Coulter Inc.

11.6.1 Company Overview

11.6.2 Types Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.7 Stryker Corporation

11.7.1 Overview

11.7.2 Types Overview

11.7.3 Financials

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 Others

Chapter 12 MRFR Conclusion

12.1 Key Findings

12.1.1 From CEO’s View Point

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Prediction of Desmoid Tumor industry

Chapter 13 Appendix

LIST OF TABLES

Table 1 Desmoid Tumor Industry Synopsis, 2017 – 2023

Table 2 Desmoid Tumor Market Estimates and Forecast, 2017 – 2023, (USD Million)

Table 3 Desmoid Tumor Market by Region, 2017 – 2023, (USD Million)

Table 4 Desmoid Tumor Market by Diagnosis, 2017 – 2023, (USD Million)

Table 5 Desmoid Tumor Market by Treatment, 2017 – 2023, (USD Million)

Table 6 Desmoid Tumor Market by End Users, 2017 – 2023, (USD Million)

Table 7 North America Desmoid Tumor Market by Diagnosis, 2017 – 2023, (USD Million)

Table 8 North America Desmoid Tumor Market by Treatment, 2017 – 2023, (USD Million)

Table 9 North America Desmoid Tumor Market by End Users, 2017 – 2023, (USD Million)

Table 10 US Desmoid Tumor Market by Diagnosis, 2017 – 2023, (USD Million)

Table 11 US Desmoid Tumor Market by Treatment, 2017 – 2023, (USD Million)

Table 12 US Desmoid Tumor Market by End Users, 2017 – 2023, (USD Million)

Table 13 Canada Desmoid Tumor market by Diagnosis, 2017 – 2023, (USD Million)

Table 14 Canada Desmoid Tumor Market by Treatment, 2017 – 2023, (USD Million)

Table 15 Canada Desmoid Tumor market by End Users, 2017 – 2023, (USD Million)

Table 16 South America Desmoid Tumor Market by Diagnosis, 2017 – 2023, (USD Million)

Table 17 South America Desmoid Tumor Market by Treatment, 2017 – 2023, (USD Million)

Table 18 South America Desmoid Tumor Market by End Users, 2017 – 2023, (USD Million)

Table 19 Europe Desmoid Tumor Market by Diagnosis, 2017 – 2023, (USD Million)

Table 20 Europe Desmoid Tumor Market by Treatment, 2017 – 2023, (USD Million)

Table 21 Europe Desmoid Tumor Market by End Users, 2017 – 2023, (USD Million)

Table 22 Western Europe Desmoid Tumor Market by Diagnosis, 2017 – 2023, (USD Million)

Table 23 Western Europe Desmoid Tumor Market by Treatment, 2017 – 2023, (USD Million)

Table 24 Western Europe Desmoid Tumor Market by End Users, 2017 – 2023, (USD Million)

Table 25 Eastern Europe Desmoid Tumor market by Diagnosis, 2017 – 2023, (USD Million)

Table 26 Eastern Europe Desmoid Tumor Market by Treatment, 2017 – 2023, (USD Million)

Table 27 Eastern Europe Desmoid Tumor Market by End Users, 2017 – 2023, (USD Million)

Table 28 Asia Pacific Desmoid Tumor Market by Diagnosis, 2017 – 2023, (USD Million)

Table 29 Asia Pacific Desmoid Tumor Market by Treatment, 2017 – 2023, (USD Million)

Table 30 Asia Pacific Desmoid Tumor market by End Users, 2017 – 2023, (USD Million)

Table 31 Middle East & Africa Desmoid Tumor Market by Diagnosis, 2017 – 2023, (USD Million)

Table 32 Middle East & Africa Desmoid Tumor Market by Treatment, 2017 – 2023, (USD Million)

Table 33 Middle East & Africa Desmoid Tumor market by End Users, 2017 – 2023, (USD Million)



LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Desmoid Tumor Market

Figure 3 Segmentation Market Dynamics for Desmoid Tumor Market

Figure 4 Global Desmoid Tumor market Share, by Diagnosis 2016

Figure 5 Global Desmoid Tumor market Share, by Treatment 2016

Figure 6 Global Desmoid Tumor market Share, by End Users, 2016

Figure 7 Global Desmoid Tumor market Share, by Region, 2016

Figure 8 North America Desmoid Tumor market Share, by Country, 2016

Figure 9 Europe Desmoid Tumor market Share, by Country, 2016

Figure 10 Asia Pacific Desmoid Tumor market Share, by Country, 2016

Figure 11 Middle East & Africa Desmoid Tumor market Share, by Country, 2016

Figure 12 Global Desmoid Tumor market: Company Share Analysis, 2016 (%)

Figure 13 Amgen Inc.: Key Financials

Figure 14 Amgen Inc.: Segmental Revenue

Figure 15 Amgen Inc.: Geographical Revenue

Figure 16 Novartis AG: Key Financials

Figure 17 Novartis AG: Segmental Revenue

Figure 18 Novartis AG: Geographical Revenue

Figure 19 Abbott Laboratories: Key Financials

Figure 20 Abbott Laboratories: Segmental Revenue

Figure 21 Abbott Laboratories: Geographical Revenue

Figure 22 Bayer AG: Key Financials

Figure 23 Bayer AG: Segmental Revenue

Figure 24 Bayer AG: Geographical Revenue

Figure 25 AbbVie Inc.: Key Financials

Figure 26 AbbVie Inc.: Segmental Revenue

Figure 27 AbbVie Inc. Geographical Revenue

Figure 28 Beckman Coulter Inc.: Key Financials

Figure 29 Beckman Coulter Inc.: Segmental Revenue

Figure 30 Beckman Coulter Inc.: Geographical Revenue

Figure 31 Stryker Corporation: Key Financials

Figure 32 Stryker Corporation: Segmental Revenue

Figure 33 Stryker Corporation: Geographical Revenue